Plasma-derived Medicinal Products
Human plasma contains many proteins which, following extraction, purification, and formulation into medicinal products are of great medical importance. Plasma-derived products provide life-saving therapies but the quantity of plasma for fractionation is limited by the number of donors. Therefore, the exchange of intermediates between manufacturers or the use of a variant manufacturing process (see below) may be possible to assure the best use of blood/plasma donations.
The Guideline on plasma-derive medicinal products provides guidance for the collection of starting material, the manufacturing and the quality control of plasma-derived medicinal products. Specific attention is given to the virus safety of these products.
Related GMP News
05.09.2024Revision of USP Chapter <1033> on Validation of Biological Assays published
05.09.2024Next Generation of Genome Editing?
05.09.2024A further Step for the SoHO Regulation
05.09.2024FDA Developments on Biosimilars
21.08.2024Update of the Overview of upcoming CBER Guidelines in 2024
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials